阳光诺和：STC007注射液临床试验按既定方案稳步推进，进展符合预期

Group 1 - The clinical trial for STC007 injection targeting postoperative pain is progressing smoothly according to the established plan, with all clinical work being conducted in an orderly manner and meeting expectations [1] - The timeline for the market application submission will be determined based on the results of the clinical trial data, statistical analysis, and preparation for registration [1] - In the domestic postoperative pain treatment market, traditional analgesics dominate, while STC007 targets the kappa opioid receptor (KOR) and has a unique mechanism that reduces central nervous system side effects such as respiratory depression and addiction, offering longer-lasting analgesia and ease of clinical use [1] Group 2 - Currently, there is only one product targeting the same receptor that is already on the market and included in the medical insurance directory, indicating a competitive landscape with limited direct competition [1] - The company will continue to monitor industry competition dynamics and focus on the clinical value and commercialization of the product, with relevant competitive information available through public industry reports and company announcements [1]